NCT06926374 Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
| NCT ID | NCT06926374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-03-25 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-03-25 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic surgery. Recently, a new robotic surgical system (Sentire Robotic Surgical System) was introduced by researchers of The Chinese University of Hong Kong (CUHK). This new robotic surgical system aims to achieve similar outcomes and standards of robotic surgery performed using the dominating system but with a significantly lower cost. The technologic innovation and development of this new robotic system is made by the Cornerstone Robotics Limited, which is based in Hong Kong. In a pilot clinical study conducted at Prince of Wales Hospital involving 55 patients, the Sentire Robotic Surgical System had demonstrated high success rate with minimal complications in patients who underwent robotic colorectal, upper gastrointestinal, and urologic surgery. Researchers of CUHK would therefore like to conduct another prospective study to further evaluate the efficacy and safety of Sentire Surgical System C1000 in major gastrointestinal and urologic surgery with expanded indications. It is believed that the results of this study will provide data to support its use for wide range of procedures with minimal access trauma, for the benefit of patients. This system will also lead to a wider range of clinical application for minimally invasive surgery with a cost-effective model.
Eligibility Criteria
General Inclusion Criteria for All Procedures: * Body mass index \<35 kg/m2 * Suitable for the listed minimally invasive surgical procedures for treatment of respective diseases * Willingness to participate as demonstrated by giving informed consent General Exclusion Criteria for All Procedures: * Contraindication to general anesthesia * Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention * Untreated active infection * Noncorrectable coagulopathy * Presence of another malignancy or distant metastasis * Emergency surgery * Vulnerable population (e.g., mentally disabled, pregnancy) Robotic Colorectal Resection Inclusion Criteria: \- Adenocarcinoma or large adenoma (not amenable to endoscopic removal) located at the colorectum (from the cecum to the anal verge) amenable to minimally invasive surgery Exclusion Criteria: * T4 tumor * Recurrent tumor * Extensive previous abdominal surgery precluding minimally invasive surgery Robotic Transanal Total Mesorectal Excision Inclusion Criteria: \- Mid/low rectal adenocarcinoma located \<12 cm from the anal verge Exclusion Criteria: * T4 tumor or involvement of circumferential resection margin even after neoadjuvant therapy * Tumor requiring multivisceral resection * Tumor requiring abdominoperineal resection; recurrent rectal tumor * T1 tumor that can be treated by local excision * Extensive previous abdominal surgery Robotic Rectopexy Inclusion Criteria: * Clinically diagnosed with previously untreated and uncomplicated rectal prolapse or enterocele Exclusion Criteria: \- Extensive previous abdominal surgery precluding minimally invasive surgery Radical Prostatectomy Inclusion Criteria: \- Clinically diagnosed with nonmetastatic adenocarcinoma of prostate Exclusion Criteria: \- Previous history of prostate surgery (e.g., transurethral resection of prostate) Total or Partial Nephrectomy Inclusion Criteria: \- Clinically diagnosed with nonmetastatic kidney cancer Exclusion Criteria: * Previous ipsilateral kidney surgery * Complex kidney anatomy (e.g., horseshoe kidney, complex renal vascular anatomy) Radical Cystectomy Inclusion Criteria: \- Clinically diagnosed with nonmetastatic bladder cancer Robotic Esophageal Hiatal Surgery and Fundoplication Inclusion Criteria: \- Clinically diagnosed with Hiatal Hernia and / or Gastroesophageal reflux disease amendable to fundoplication Exclusion Criteria: \- Previous history of laparotomy precluding minimally invasive surgery Robotic Gastrectomy Inclusion Criteria: \- Clinical diagnosis of gastric tumor (Adenocarcinoma or Gastrointestinal Stromal Tumor (GIST)) amendable to minimally invasive radical gastrectomy Exclusion Criteria: \- Previous history of laparotomy precluding minimally invasive surgery Robotic Esophagectomy Inclusion Criteria: \- Clinical diagnosis of carcinoma of esophagus amendable to minimally invasive esophagectomy Exclusion Criteria: \- Esophageal carcinoma after definitive chemoradiotherapy and indicated for salvage esophagectomy Robotic Cholecystectomy Inclusion Criteria: \- Symptomatic gallbladder stones clinically indicated for laparoscopic cholecystectomy Exclusion Criteria: * Acute cholecystitis * Previous history of abdominal surgery
Contact & Investigator
Simon SM Ng, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT06926374 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06926374 currently recruiting?
Yes, NCT06926374 is actively recruiting participants. Contact the research team at simonng@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT06926374 trial being conducted?
This trial is being conducted at Hong Kong, China.
Who is sponsoring the NCT06926374 clinical trial?
NCT06926374 is sponsored by Chinese University of Hong Kong. The principal investigator is Simon SM Ng, MD at Chinese University of Hong Kong. The trial plans to enroll 90 participants.